Dupont aca and the Beckman Glucose Analyzer for glucose, and to the Dupont aca and the Technicon SMA 12/60 for urea. We also measured glucose in cerebrospinal fluid, with use of aqueous standards. Instrument stability during 39 days without recalibration was evaluated. Results from the EKTACHEM compared favorably with those from the other instruments with respect to precision, accuracy, analytical recovery, instrument and reagent stability, and (non-drug) interferences. General instrument performance was excellent, with little downtime. The instrument was enthusiastically accepted by our laboratory personnel.
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The "EKTACHEM Glu/BUN Analyzer" (Eastman Kodak Co., Rochester, NY 14650) is a novel clinical instrument, designed to measure urea nitrogen and glucose by use of Kodak's thin, multilayer film technology (1, 2) . Glucose is measured by a modification of Trinder's procedure, with glucose oxidase (EC 1.1.3.4) and peroxidative coupling of a naphthol compound to aminoantipyrine.
For urea, the reaction is urease (EC 3.5.1.5)= catalyzed hydrolysis of urea, liberating ammonia, which reacts with a protonated merocyanine compound to form an indicator dye. Buffers, enzymes, and indicators are incorporated into multiple, thin, dry layers, which are applied to a 16-mm square transparent support base (the "slide" 
Materials and Methods

Equipment
Methods
The SMA 12/60 urea procedure was the unmodified diacetyl monoxime method. Glucose and urea procedures used with the aca were the standard enzymic methods provided by DuPont.
Glucose was measured by the oxygen rate method with the Beckman Glucose Analyzer.
Reagents
Glucose and urea reagents for the Kodak instrument were supplied by Kodak in cartridges containing 50 slides. Unless otherwise specified, the cartridges were stored at 4 #{176}C until the day of use. These samples were each assayed five times with the Kodak Analyzer.
Glucose concentration was linearly related to instrument reading from 230 to 5920 mg/L.
Urea linearity was studied in two separate experiments. In the first, the range covered 270 to 1210 mg/L. A fresh human serum pool was prepared (urea by aca, 270 mg/L). A second solution was prepared by adding urea to a portion of the initial pool (urea by aca, 1210 mg/L). Appropriate mixtures of the two gave six concentrations over the range, and each was assayed five times for urea with the EKTACHEM Analyzer. The second linearity study included the range 40 to 380 mg/L. Kodak Control II (urea by aca, 380 mg/L) and fresh human serum (urea by ace, 40 mg/L) were mixed to provide seven concentrations over the range; each was assayed five times in the Kodak Analyzer. Readings for urea with the EKTACHEM were linearly related to concentration from 40 to 1210 mg/L.
Analytical Recovery
A fresh pooled specimen of human serum was analyzed five times for urea and glucose with the Kodak Analyzer (urea = 256 mg/L, glucose = 1082 mg/L). Glucose (108, 200, and 480 mg) and urea (25, 50, and 94 mg) were weighed into 100-mL aliquots of the pool and each solution was analyzed five times. Analytical recovery for both glucose and urea was 96 to 102%.
Interference
We tested the effect of hemolysis, lipemia, and icterus. We added known amounts of hemoglobin (0-5600 mg/L), assayed in a fresh hemolysate, to a serum pool and then measured five times for glucose (1000-5000 mg/L) and urea (200-600 mg/L).
For the lipemia study, 14 turbid serum samples were assayed in duplicate for urea (70-400 mg/L) and glucose Table 1 summarizes the between-run precision studies. The data are presented for a baseline study and for daily qualitycontrol data collected during two months after the baseline study. The baseline study or performance-check period accords with the NCCLS protocol (3).
Results
Between-Run Precision
The object of the baseline study was to establish a reference data base for future comparative studies. Kodak and LederRate controls (three concentrations each) were assayed in triplicate twice daily for 10 working days. As specified in the NCCLS protocol (3), controls were interspersed with randomly chosen patients' samples. Over a wide range of concentrations, the between-run precision for glucose and urea on the Kodak Analyzer was excellent.
Within-Run Precision
Eleven experiments (n = 24 to 59) were performed during six weeks with use of pooled reconstituted lyophilized controls in the low, medium, and high range for glucose and urea. The CV's for glucose were consistently less than 1.5%; the CV's for urea ranged from 1.0 to 3.4%.
Linearity
For the low-range glucose study we used a saline solution of human albumin, 41 g/L, and human globulin, 25 mg/L (Sigma Chemical Co., St. Louis, MO 63178), with glucose added to the solution. The solution (glucose, 1400 mgfL) was analyzed five times for glucose in the Kodak Analyzer. Appropriate dilutions were made with the initial protein-based solution to provide five glucose concentrations ranging from 230 to 1400 mg/L; each was assayed five times with the Kodak Analyzer.
For the high-range study, we used a pooled specimen of serum, assayed for glucose five times with the Kodak Analyzer (glucose = 1080 mg/L). We added glucose to a portion of this pool to give a final glucose concentration of 5920 For the icterus study, samples from 29 patients with values for total bilirubin ranging from 14 to 174 mg/L were assayed in duplicate for glucose (700-6000 mg/L) and urea (80-1000 mg/L) with the four instruments.
We observed no effect on results for glucose or urea over a wide range of hemoglobin, lipid, and bilirubin concentrations. 
Reagent Stability
We analyzed Kodak controls no. 1, 2, and 3 daily, in duplicate, during four weeks, using reagent slides (same lot number) left at room temperature.
These data were compared to similar data from refrigerated reagents (same lot numbers). Room temperature ranged from 20 to 26 #{176}C and the relative humidity from 2 to 77%. We observed no effect on urea measurements.
We found a good correlation for glucose during the first two weeks of the study. The glucose values were inconsistently increased during the last two weeks. Reagent slides kept for extended periods should be stored refrigerated. For short-term use of up to two weeks, they may be stored at room temperature.
Calibration Stability
The purpose was to determine how frequently the Kodak instrument should be re-calibrated. The instrument was calibrated for glucose and urea on day 1 according to the standard protocol of Kodak, and not again for 39 days. Fresh Kodak and LederRate controls were reconstituted each working day and analyzed in the morning and late afternoon. The same lots of cartridge packs were used during the experiment, the results of which are presented in Table 2 . CV's for this test period were consistently lower and the mean for each control was essentially the same as with daily recalibration (refer to Table 1 ). Evidently there is no loss of precision or accuracy if the instrument is not recalibrated daily.
Sample Size
We determined that the minimum volume necessary to perform the two tests was 30 zL, or 15 zL for only one test.
Anticoagulant Study
We assayed 75 samples (sodium fluoride anticoagulant) for glucose, in duplicate, with the Kodak and Beckman Analyzers. Glucose ranged from 280 to 5560 mg/L. There was good correlation between instruments for glucose values up to 3000 mg/L. The Kodak instrument gave lower results (3 to 7%) for glucose >3000 mg/L (n = 6). The same group of fluoridetreated plasma samples were analyzed for urea in the Kodak Analyzer and the aca. There was good correlation for normal range. Results for the EKTACHEM were up to 20% lower when urea exceeded 400 mg/L.
In a separate study, we compared serum and fluoride- samples, with glucose ranging from 260 to 5570 mg/L. Glucose results for two of the plasma samples with glu#{235}ose >3000 mgfL were 5 and 7% lower than for serum. We conclude that samples anticoagulated with sodium fluoride should not be used for urea. Our data for glucose indicate fluoride-treated plasma will be satisfactory; however, we had few samples with glucose >3000 mg/L.
In a more limited study involving 12 patients, we compared urea and glucose in serum and plasma in the Kodak Analyzer, with use of EDTA and heparin as anticoagulants.
For both glucose (570-1950 mg/L) and urea (70-540 mg/L), such plasma samples gave results that compared favorably with those for the serum samples.
Protein Effects
In a study of 43 patients' serum samples with low total proteins showed good correlation on all four instruments. We prepared a more concentrated pooled specimen of human serum by molecular filtration (Immersible Molecular Separator; Mulipore Corp., Bedford, MA 01739) and diluted it with isotonic saline to obtain a range of total proteins from 0 g/L (saline) to 150 g/L (concentrated pool). The glucose and urea concentrations were adjusted by adding urea and glucose so that the glucose and urea concentrations were respectively the same in each solution. For those solutions with total protein between 30 and 120 g/L, glucose was found to be within 10% of the weighed-in value; for those with <30 g/L or >120 g/L, the results obtained for glucose were significantly below the expected.
When the data were normalized for variation in sample-spot size, glucose values were within 5% of the expected value for protein concentrations of 0-120 g/L. Results were similar for urea: values were within 10% of the expected value when protein concentration was 30-120 g/L. In a separate experiment (protein range 0-150 g/L) the urea showed a consistent 15% negative bias over the entire range of protein concentration.
Protein effects are attributed to variation in spot diameters at extreme protein values (viscosity effects) and to protein interaction with the thin film matrix (personal communication, Eastman Kodak Co.). We believe that some of the van- 
Albumin Solutions as Diluents
In six studies we used commercially available albumin, with water or saline as a diluent. We found a wide range of negative bias on comparing the Kodak Analyzer to the other instruments; we concluded that no commercial albumin solution is satisfactory for use as a diluent with the Kodak Analyzer. The data are presented in Figures 1 and 2 .
Glucose in Cerebrospinal Fluid
Ortho Spinal Fluid Control (glucose, 590 mg/L) was analyzed with the EKTACHEM (calibrated with aqueous standards) five times a day for nine days. The mean value obtained was 582 mg/L (CV 1.7%). We conclude that the EKTACHEM can be used to measure glucose in spinal fluid when calibrated with aqueous standards, and that Ortho Cerebrospinal Fluid Control is a satisfactory quality-control material.
Patient Correlation Study
We compared results during 21 weeks for glucose and urea determined in 160 patients' sera with the Kodak Analyzer, the aca, and the Beckman Analyzer for glucose, and the ace and the SMA 12/60 for urea. All samples were run in duplicate on the instruments except an occasional SMA-12 specimen which was run single. The glucose range was 210-5730 mg/L, the urea range 50-1200 mg/L. Figures 3-6 show the results. There was those obtained with the other instruments, for both glucose and urea in patients' sera. Accuracy, precision, and recovery were well within generally accepted limits. 
Discussion
We used more than 17 000 slides in the instrument during the 21-week evaluation.
In 
